Alteogen Signs $3.2 Billion Licensing Deal With Novartis
A view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170.KQ) has signed a technology…
Alteogen Licenses ALT-B4 Platform to Novartis in Deal Worth Up to $3.2 Billion
An exterior view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170) has signed a…
Roche Unveils Subcutaneous Tecentriq for Lung Cancer Treatment in India, ETPharma
New Delhi: Swiss Pharma major, Roche has commercially launched a subcutaneous (SC) version of its blockbuster cancer immune-therapy…